SII seeks market authorisation from DCGI for India’s first qHPV vaccine against cervical cancer
The firm has applied for market authorisation after completing the phase-II/III clinical trial with support of the Department of…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
DCGI
Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabs
The Drugs Controller General of India (DCGI) had granted emergency use permission to Sputnik Light, subject to certain regulatory…
Bharat Biotech seeks DCGI nod for phase-II/III Covaxin booster trial
The study is likely to be conducted at six sites, including AIIMS Delhi and Patna
Government panel recommends Corbevax for emergency use in kids aged five to 11 years
Biological E's Corbevax is being used to inoculate children against COVID-19 in the age group of 12 to 14 years
DCGI gives nod to phase-III clinical trial of Covovax
The vaccine has not been included in the country's inoculation programme against COVID-19
DCGI gives EUA nod to SII’s Covovax for 12-17 years’ age group
It is the fourth vaccine to receive the regulator's nod for use among those below 18 years
Biological E seeks EUA for Corbevax for children in five-12 age group
Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine against COVID-19
Zydus receives DCGI approval for Oxemia to treat anaemia in CKD patients
OxemiaTM (Desidustat) is an oral tablet formulation which is the first-in-India alternative to injectable…
Government panel recommends permission for phase-III trial of Covovax as booster dose in adults
The Drugs Controller General Of India (DCGI) has already approved Covovax for restricted use in emergency situations in adults on…
COVID-19 vaccine from Biological E.,CORBEVAX gets EUA from DCGI for 12-18 age group
DCGI has already approved CORBEVAX for restricted use in emergency situation among adults